e-learning
resources
Munich 2006
Monday 04.09.2006
Cardiovascular pathophysiology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prevalence of pulmonary hypertension in patients with plasma lupus anticoagulant
A. Borak, I. Pabinger, I. M. Lang (Vienna, Austria)
Source:
Annual Congress 2006 - Cardiovascular pathophysiology
Session:
Cardiovascular pathophysiology
Session type:
Thematic Poster Session
Number:
2388
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Borak, I. Pabinger, I. M. Lang (Vienna, Austria). Prevalence of pulmonary hypertension in patients with plasma lupus anticoagulant. Eur Respir J 2006; 28: Suppl. 50, 2388
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
The physiology of breathlessness
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Effectiveness of ²Korargin² in the therapy of pulmonary arterial hypertension in patients with systemic lupus erythematosus
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study
Source: Eur Respir J, 53 (2) 1800081; 10.1183/13993003.00081-2018
Year: 2019
Endothelium dysfunction in systemic lupus erythematosus patients with pulmonary hypertension
Source: Annual Congress 2011 - Clinical features of pulmonary hypertension
Year: 2011
Early outcomes of patients with systemic lupus erythematosus and antiphospholipid syndrome after pulmonary endarterectomy
Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension
Year: 2016
Pulmonary hypertension in patients with lupus: Prevalence, etiology and risk factors
Source: Annual Congress 2012 - Pulmonary circulation: clinical databases and registries
Year: 2012
Charactaristics and prognosis of autoimmune antibody-positive patients of idiopathic pulmonary arterial hypertension
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Immunosuppression in systemic lupus erythematosus associated pulmonary arterial hypertension (SLE-APAH): Improvement in exercise and functional capacity
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Pulmonary arterial hypertension and systemic lupus erythematosus
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Secondary pulmonary hypertension in chronic obstructive pulmonary disease and systemic lupus erythematosus- pathophysiology and treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 59s
Year: 2004
Prevalence of lupus anticoagulant in patients undergoing bronchoscopy
Source: Annual Congress 2010 - Management of sarcoidosis and lung manifestations of systemic diseases
Year: 2010
Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis
Source: Eur Respir J, 51 (4) 1701197; 10.1183/13993003.01197-2017
Year: 2018
Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension
Source: Eur Respir J, 52 (4) 1801745; 10.1183/13993003.01745-2018
Year: 2018
Systemic inflammation and pulmonary hypertension in patients with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 142s
Year: 2007
Prevalence of pulmonary hypertension in patients after splenectomy
Source: Annual Congress 2008 - Acute and chronic pulmonary thromboembolic disease
Year: 2008
Prevalence of pulmonary hypertension in limited and diffuse scleroderma
Source: Eur Respir J 2003; 22: Suppl. 45, 465s
Year: 2003
The nitroxidergic system state at systemic lupus erythematosus-associated pulmonary hypertension
Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension
Year: 2010
Predictors of pulmonary artery hypertension in patients with systemic sclerosis
Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach
Year: 2012
Type of anticoagulant therapy as a risk factor for the severity of chronic thromboembolic pulmonary hypertension
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Pulmonary hypertension in systemic scleroderma
Source: Eur Respir J 2003; 22: Suppl. 45, 269s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept